Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.

Expert review of anticancer therapy - 1 Jul 2016

Amaral Teresa, Nouri Noura, Garbe Claus

Abstract excerpt

INTRODUCTION: In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 mutations. This paper addresses the safety and efficacy of cobimetinib, when used in combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanoma

Share to Piperidines

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 27219630
DOI: 10.1080/14737140.2016.1192469

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.PMID 27219630Read ↗

Cobimetinib and vemurafenib for the treatment of melanoma.Semantic proximity Read ↗

Cobimetinib.Semantic proximity Read ↗

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.Semantic proximity Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.Semantic proximity Read ↗

Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

[BRAF-MEK inhibitor therapy in melanoma].Semantic proximity Read ↗

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Semantic proximity Read ↗

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.